This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items,” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-23-2183392 and the solicitation is issued as a Request for Quotes (RFQ).
This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2023-04 June 2, 2023.
The North American Industry Classification System (NAICS) code for this procurement is 334516, Analytical Laboratory Instrument Manufacturing, with a size standard of 1000 employees. The requirement is being competed with a brand name restriction, without a small business set-aside.
The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following Brand Name Supplies:
- Chromium NextGEM SC 3' Kit v3.1, 16 rxns, product code 1000268, quantity 1
- Chromium NextGEM SC Chip G, 48 rxns, product code 1000120, quantity 1
- Chromium iX & Accessory Kit,12 Mo. Warranty, product code 1000328, quantity 1
- Shipping & Handling, quantity 1
Rocky Mountain Laboratories, Laboratory of Neurological Infections and Immunity (LNII), conducts basic and applied research on viruses, prions, and prion-like protein aggregates in biosafety level-2 to maximum containment biosafety level-4 environments to uncover fundamental mechanisms of agent replication and neuropathogenesis to inform novel approaches to diagnostics and therapeutics. This work employs investigations in small animal and advanced tissue culture models to apply quantitative and systems approaches for analysis of complex cellular interactions and immune responses.
The lab’s first generation existing 10X Genomics Controller instrumentation that has been used for processing many samples for single sequencing projects has limited throughput and sample type capability. The 10X Genomics offers a next generation upgrade to this platform. The Chromium iX instrument upgrade will enable processing of not only fresh tissue and cells but provides the valuable option of sequencing from formalin fixed paraffin embedded stored samples, allowing us to examine transcription at the single cell level from specific samples of known importance. It can also be modified in the future for high throughput demands if needed.
Place of Performance: NIH, NIAID, RML, DIR, LNII, 903 South 4th Street, Hamilton, MT 59840, United States. FOB: Destination
The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following: technical capability to meet the requirements and price.
The following FAR provisions apply to this acquisition:
FAR 52.212-1 Instructions to Offerors Commercial Items (MAR 2023)
FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (DEC 2022)
FAR 52.204-7 System for Award Management (OCT 2018)
(Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure FAR 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record)
FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements – Representation (JAN 2017)
FAR 52.204–26 Covered Telecommunications Equipment or Services-Representation
(OCT 2020) *** Must complete representation if attached to this solicitation- see attachment 52.204-26
The following FAR contract clauses apply to this acquisition:
FAR 52-212-4 Contract Terms and Conditions Commercial Items (DEC 2022)
FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (JUNE 2023)
*The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting.
FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (MAR 2023)
FAR 52.204-13 System for Award Management Maintenance (OCT 2018)
FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021)
HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (DEC 2015)
52.252-2 -- Clauses Incorporated by Reference. (FEB 1998)
This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://farsite.hill.af.mil/vffara.htm
By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov).
Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax.
Submission shall be received not later than Thursday, August 24, 2023 @ 11:00 AM EST
Offers may be e-mailed to Rita Davis (E-Mail/rita.davis@nih.gov). Offers shall include RFQ number in the subject line (RFQ-NIAID-23-2183392). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f).
All responsible sources may submit an offer that will be considered by this Agency.
Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Rita Davis @ rita.davis@nih.gov.
